NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Thomas A. Hope, Lisa Bodei, Jennifer A. Chan, Ghassan El‐Haddad, Nicholas Fidelman, Pamela L. Kunz, Josh Mailman, Yusuf Menda, David C. Metz, Erik Mittra, Daniel A. Pryma, Diane Reidy‐Lagunes, Simron Singh, Jonathan Strosberg
Abstract
With the growing use of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. In this document, we review the literature on the use of 177Lu-DOTATATE in neuroendocrine tumors (NETs) of different primary origin, discuss issues of
Topics & Concepts
Radionuclide therapyPeptide receptorMedicineSelection (genetic algorithm)RadionuclideNuclear medicineRadionuclide imagingDOTANeuroendocrine tumorsMedical physicsInternal medicineChemistryReceptorChelationComputer sciencePhysicsNuclear physicsArtificial intelligenceOrganic chemistryNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and Treatments